# Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

> **NCT01339871** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 152 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT01339871
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-20
- **Primary completion:** 2017-06-07
- **Final completion:** 2017-06-07
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2017-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01339871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01339871, "Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01339871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*